MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Bayer AG

Closed

SectorFinance

21.29 -0.37

Overview

Share price change

24h

Current

Min

20.405

Max

21.835

Key metrics

By Trading Economics

Income

3.9B

-328M

Sales

1.8B

12B

P/E

Sector Avg

30.9

22.015

EPS

1.05

Dividend yield

0.49

Profit margin

-2.796

Employees

90,587

EBITDA

615M

1.7B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+25.54% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.49%

3.90%

Market Stats

By TradingEconomics

Market Cap

422M

22B

Previous open

21.66

Previous close

21.29

News Sentiment

By Acuity

26%

74%

87 / 542 Finance

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Bayer AG Chart

Past performance is not a reliable indicator of future results.

Related News

24 Mar 2025, 09:37 UTC

Major Market Movers

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 Mar 2025, 11:21 UTC

Earnings

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 Mar 2025, 08:45 UTC

Earnings

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 Mar 2025, 07:26 UTC

Earnings

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2 Apr 2025, 09:27 UTC

Hot Stocks

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 Mar 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

5 Mar 2025, 13:39 UTC

Market Talk
Earnings

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 Mar 2025, 13:26 UTC

Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 Mar 2025, 08:30 UTC

Market Talk
Earnings

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 Mar 2025, 06:41 UTC

Earnings

Bayer Launches Plan to Boost Profitability at Crop Science

5 Mar 2025, 06:40 UTC

Earnings

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 Mar 2025, 06:39 UTC

Earnings

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 Mar 2025, 06:39 UTC

Earnings

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 Mar 2025, 06:36 UTC

Earnings

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 Mar 2025, 06:35 UTC

Earnings

Bayer Guidance is on a Currency Adjusted Basis

5 Mar 2025, 06:34 UTC

Earnings

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 Mar 2025, 06:34 UTC

Earnings

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 Mar 2025, 06:33 UTC

Earnings

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 Mar 2025, 06:33 UTC

Earnings

Bayer Sees 2025 Sales EUR45B-EUR47B

5 Mar 2025, 06:32 UTC

Earnings

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 Mar 2025, 06:31 UTC

Earnings

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 Mar 2025, 06:31 UTC

Earnings

Bayer 4Q Net Loss EUR335M

5 Mar 2025, 06:31 UTC

Earnings

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 Mar 2025, 06:31 UTC

Earnings

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 Mar 2025, 06:31 UTC

Earnings

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 Mar 2025, 06:31 UTC

Earnings

Bayer 4Q Sales EUR11.73B

13 Jan 2025, 21:05 UTC

Top News

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 Jan 2025, 15:06 UTC

Acquisitions, Mergers, Takeovers

Bayer Didn't Disclose Financial Details

9 Jan 2025, 15:05 UTC

Acquisitions, Mergers, Takeovers

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 Jan 2025, 15:05 UTC

Acquisitions, Mergers, Takeovers

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

25.54% upside

12 Months Forecast

Average 26.89 EUR  25.54%

High 33 EUR

Low 22 EUR

Based on 10 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

10 ratings

1

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

N/A / 22.575Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

87 / 542 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.